To study the efficacy of a therapeutic HIV vaccine consisting of autologous myeloid dendritic cells pulsed ex vivo with high doses of inactivated autologous HIV-1, in HIV-1 infected patients in a very early stages of the disease (CD4 > 450 x 10 6 /L).
To analyze the HIV-1 humoral and cellular immune responses induced by this immune-based therapy.

Start Date01 Nov 2006

Sponsor / Collaborator

Hospital Clínic de Barcelona

100 Clinical Results associated with Dendritic cells vaccine(Hospital Clinic of Barcelona)

100 Translational Medicine associated with Dendritic cells vaccine(Hospital Clinic of Barcelona)

100 Patents (Medical) associated with Dendritic cells vaccine(Hospital Clinic of Barcelona)

Literatures (Medical) associated with Dendritic cells vaccine(Hospital Clinic of Barcelona)

01 Jul 2010·International Journal of UrologyQ3 · MEDICINE

Reduction of major histocompatibility complex class I expression on bladder carcinoma following tumor antigen‐pulsed dendritic cell vaccine: Implications for immunoresistance in therapy

Q3 · MEDICINE

Article

Author: Wenzhen Shi ; Jiangying Chen ; Mengqiang Li ; Huili Wang ; Zhijun Xi ; Enci Xu ; Xuejun Jiang

Objectives: To clarify the relationship between a decreased major histocompatibility complex class I (MHC‐I) expression on bladder tumors and decreased immunological efficacy of tumor antigen‐pulsed dendritic cell vaccine in a rat bladder carcinoma model induced by N‐methyl‐N‐nitrosourea irrigation.Methods: Enzyme‐linked immunosorbent assay was used to evaluate interferon‐gamma concentration in the serum and colorimetric lactate dehydrogenase release assay in vitro was used to test the cytotoxicity capability of T lymphocytes. MHC‐I expression on tumor cells was detected by flow cytometry and analyzed with CellQuest software.Results: The tumor antigen sensitized dendritic cell vaccine group showed decreased hyperplastic formations, lower pathological stages in rat bladders and more potent cytotoxicity activity (P < 0.001) than the dendritic cell vaccine group. Additionally, immunization with pulsed dendritic cell vaccine induced higher specific cytokine production of interferon‐gamma. Nevertheless, a decreased MHC‐I expression on bladder tumors was tested after immunotherapy by pulsed dendritic cell vaccine on week 15. As expected, the cytotoxic activity of T lymphocytes from rats on tumor cells with low MHC‐I expression was also decreased to 19.70 ± 4.82% as compared with tumor cells with high MHC‐I (52.10 ± 8.66%, P = 0.005).Conclusions: Tumor antigen sensitized dendritic cell vaccine has beneficial activity on N‐methyl‐N‐nitrosourea‐induced bladder cancer in situ in rats, but therapeutic responses are accompanied by decreased MHC‐I expression on tumors, possibly suggesting poor long‐term therapeutic outcomes.

01 May 2000·The Journal of ImmunologyQ2 · MEDICINE

Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine

Q2 · MEDICINE

Article

Author: Levy, Ronald ; Timmerman, John M.

AbstractThe unique Ag-presenting capabilities of dendritic cells (DCs) make them attractive vehicles for the delivery of therapeutic cancer vaccines. While tumor Ag-pulsed DC vaccination has shown promising results in a variety of murine tumor models and early clinical trials, the optimal form of tumor Ag for use in DC pulsing has not been determined. We have studied DC vaccination using alternative forms of a soluble protein tumor Ag, the tumor-specific Ig idiotype (Id) expressed by a murine B cell lymphoma. Vaccination of mice with Id-pulsed DCs was able to induce anti-Id Abs only when the Id was modified to constitute a hapten-carrier system. DCs pulsed with Id proteins modified to include foreign constant regions, foreign constant regions plus GM-CSF, or linkage to keyhole limpet hemocyanin (KLH) carrier protein were increasingly potent in their ability to elicit anti-Id Abs. Vaccination with Id-KLH-pulsed DCs induced tumor-protective immunity superior to that obtained with Id-KLH plus a chemical adjuvant, and protection was not dependent upon effector T cells. Rather, protection was associated with the induction of high titers of anti-Id Abs of the IgG2a subclass, characteristic of a Th1 response. These findings have implications for the design of therapeutic Ag-pulsed DC vaccines for cancer immunotherapy in humans.

British Journal of Cancer

Hypoxic tumor cell line lysate-pulsed dendritic cell vaccine exhibits better therapeutic effects on hepatocellular carcinoma

Article

Author: Jeng, Long-Bin ; Liao, Yu-Wen ; Shyu, Woei-Cherng ; Shih, Fu-Ying ; Teng, Chiao-Fang

BACKGROUNDDendritic cell (DC) vaccine is a promising immunotherapy for hepatocellular carcinoma (HCC) via triggering antigen-specific anti-tumor immunity. Hypoxia contributes to higher level and broader spectrum of antigen expression in tumor cells.METHODSThis study aims to compare immunological activity and therapeutic efficacy between hypoxic and normoxic HCC cell line lysate-pulsed DC vaccines.RESULTSThe results showed that hypoxic HCC cell line lysate-pulsed DC vaccines exhibited a stronger activity in producing interleukin-12 and promoting T cell proliferation and cytotoxicity in vitro. In HCC mice, hypoxic HCC cell line lysate-pulsed DC vaccines displayed a better efficacy in improving survival time and tumor volume and inducing intratumoral cytotoxic T cell infiltration and activation as well as tumor cell apoptosis. Adenylate kinase 4-derived antigens were important for hypoxic HCC cell line lysate-pulsed DC vaccine-elicited T cell killing.CONCLUSIONSIn conclusion, this study demonstrated hypoxic HCC cell line lysate-pulsed DC vaccine as a potential therapeutic strategy for HCC.

100 Deals associated with Dendritic cells vaccine(Hospital Clinic of Barcelona)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	Spain	Hospital Clínic de Barcelona	01 Nov 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Dendritic cells vaccine(Hospital Clinic of Barcelona)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation